Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2566 to 2580 of 8899 results

  1. Orforglipron for managing overweight and obesity ID6516

    In development Reference number: GID-TA11650 Expected publication date: TBC

  2. Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people of any age [ID6400]

    Awaiting development Reference number: GID-TA11509 Expected publication date: TBC

  3. Surgical mesh for ventral hernias

    In development Reference number: GID-HTE10080 Expected publication date: TBC

  4. Selinexor + pomalidomide + dexamethasone for Multiple myeloma [TSID12333]

    Awaiting development Reference number: GID-TA11938 Expected publication date: TBC

  5. Selinexor with ruxolitinib for treating splenomegaly or symptoms in myelofibrosis untreated with a JAK inhibitor [TSID12341]

    Awaiting development Reference number: GID-TA11941 Expected publication date: TBC

  6. Luspatercept for a-thalassemia [TSID12340]

    Awaiting development Reference number: GID-TA11940 Expected publication date: TBC

  7. Bictegravir-Lenacapavir for HIV-1 infection [TSID12343]

    Awaiting development Reference number: GID-TA11943 Expected publication date: TBC

  8. Tirzepatide for reducing the risk of major adverse cardiovascular events in people with type 2 diabetes and cardiovascular disease [TSID12347]

    Awaiting development Reference number: GID-TA11945 Expected publication date: TBC

  9. Suspected Cancer: recognition and referral (update)

    In development Reference number: GID-NG10443 Expected publication date:  25 March 2026

  10. Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 13 February 2026.

  11. Guidance on the use of electroconvulsive therapy: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 16 February 2026.

  12. Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID6575]

    In development Reference number: GID-TA11742 Expected publication date:  05 August 2026

  13. Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive early breast cancer [ID6620]

    Awaiting development Reference number: GID-TA11403 Expected publication date: TBC

  14. d-NAV for optimization of personal insulin management in adults with type 2 diabetes (MT696)

    Topic prioritisation

  15. COLOFIT algorithm to guide colorectal cancer pathway referral in primary care: early value assessment

    In development Reference number: GID-HTE10011 Expected publication date: TBC